Bristol-Myers Squibb (BMS)

Bristol Myers Squibb Appoints EVP and Announces Major US Investment

Bristol Myers Squibb appoints Cari Gallman as EVP and invests $40 billion in the US over 5 years.

Terremoto Biosciences Appoints Charles Baum as CEO

US biotechnology company Terremoto Biosciences has appointed Charles Baum CEO. He succeeds Peter Thompson, who will continue to serve as Terremoto’s board chairperson.

BMS to Invest $400 Million in Expansion of Dublin Site

Bristol Myers Squibb (BMS) wants to invest $400 million for the construction and design of a sterile drug product (SDP) facility at its Cruiserath campus in Dublin, Ireland, significantly expanding manufacturing and laboratory capacity at the site.

Bristol Myers Squibb Acquires RayzeBio

Bristol Myers Squibb will acquire RayzeBio for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.

Bristol Myers Squibb Takes Over Karuna Therapeutics

Bristol Myers Squibb (BMS) and Karuna Therapeutics have entered into a definitive merger agreement under which the US drug maker has agreed to acquire the Boston-based biopharmaceutical company for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the BMS and Karuna Boards of Directors.

Bristol-Myers Squibb to Acquire Mirati for up to $5.8 Billion

Bristol-Myers Squibb (BMS) announced that it will acquire Mirati Therapeutics for up to $5.8 billion. BMS is to pay $58.00 per share in cash, for a total equity value of $4.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.

Delivering Quality with Speed for European Market

In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and the goals of the European expansion.

Lotte Outlines Plans to Become Major CDMO Player

Lotte Biologics, part of South Korean conglomerate Lotte, has detailed expansions plans for the business as it embarks on a path to become a top 10 CDMO by 2030.

BMS Sues Astra Zeneca in Cancer Drug Patent Row

Bristol-Myers Squibb (BMS) is suing AstraZeneca Pharmaceuticals, alleging that the Anglo-Swedish drugmaker’ Imfinzi to treat lung and bladder cancer infringes several patents related to its blockbuster Opdivo.

WuXi STA Closes Purchase of Swiss BMS plant

WuXi STA, CDMO subsidiary of WuXi AppTec, has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland, from US pharma Bristol Myers Squibb. The Chinese company, which announced the purchase plans earlier this year, said the state-of-the-art facility significantly enhances its European capacity.

Bristol Myers Squibb Licenses Agenus Antibody

US drugmaker Bristol Myers Squibb has signed an exclusive license agreement for Agenus’ proprietary bispecific antibody program AGEN1777, that blocks TIGIT and a second undisclosed target.

Bristol Myers Squibb Builds Dutch Cell Therapy Site

US drugmaker Bristol Myers Squibb has chosen Leiden in the Netherlands for a new cell therapy manufacturing site in Europe as it continues to expand and develop treatments for patients with aggressive hematological cancers.

China’s WuXi Buys Bristol Myers Squibb’s Swiss Plant

China contract development and manufacturing organization (CDMO) WuXi STA has agreed to buy Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland, for an undisclosed sum. The site will be WuXi STA’s first facility in Europe. The transaction is expected to complete during the second quarter, subject to the usual conditions and regulatory approvals.

Bristol Myers Squibb Takes Heart Drug Firm MyoKardia

Bristol Myers Squibb is buying cardiovascular specialist MyoKardia for $13.1 billion, gaining rights to mavacamten, an experimental heart disease treatment that could have blockbuster potential.

Technology and Innovation in the Pharmaceutical Industry

FTC Approves $74 Billion BMS-Celgene Deal

Injecting Growth and Innovation

Trend Barometer of Specialty Chemicals Industry

Catalent Buys Facilities in US and Italy

Catalent Buying BMS Site in Italy

BMS Shareholders Greenlight Celgene Deal

The Need for Innovation in Pharmaceutical Manufacturing

Starboard Backs Away from BMS-Celgene Bust-up

BMS Shareholders Fight Celgene Takeover

Activist Starboard Meets BMS Management

Celgene Wins Patent Row, Gets Generic Rival

BMS-Celgene Deal May be in Danger

Bristol-Myers Squibb Takes Celgene for $74 Billion

Opportunities for Western CDMOs in China

J&J wins $55 Million Talc Lawsuit

Bristol-Myers Squibb and Flatiron in RWE Pact

Bristol-Myers Squibb and Nektar in Anticancer Pact

Pfizer Mulls Sale of Consumer Health Unit

US Court Ruling May Curb Drug Suit “Tourism”

Drug Patent Losses Worth Billions Seen in 2017